热门资讯> 正文
TX 45引用Raymond James的Tectual开局表现优于Raymond James
2024-11-21 01:45
- Raymond James has started coverage of Tectonic Therapeutic (NASDAQ:TECX) with an outperform rating, citing its drug candidate TX45.
- The investment firm said it believes the company's relaxin mimetic drug candidate TX45 for the treatment of group 2 pulmonary hypertension is potentially best-in-class. It noted that relaxin mimetics remains an active area for Big Pharma R&D, citing Eli Lilly (LLY) and AstraZeneca (AZN).
- “We believe TECX’s platform has enabled them to design a molecule with superior PK/PD vs the competition, and if successful, we think TX45 could become a multi-billion dollar drug,” the firm added.
- Raymond James said it sees several value inflection points for the stock over the next approximately 12 to 24 months. The firm set its price target for the stock at $65.
More on AVROBIO
- Tectonic Therapeutic: Interesting CV Disease Drug Developer
- Tectonic draws bullish view at Wells Fargo on lead asset
- Historical earnings data for AVROBIO
- Financial information for AVROBIO
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
